PGI2 synthesis in vivo in the lupus anticoagulant syndrome was in the case reported by Carreras et al,"' in whom the plasma concentration of 6-oxo-PGF,,,. the stable hydrolysis product of PGI2, was fit to be reduced. It has subsequently become evident, however, that radioimmunoassay of plasma 6-oxo-PGF1, gives highly inaccurate values. '5
We therefore used gas chromatography/negative ion electron capture mass spectrometry (the most sensitive and specific existing method) to determine plasma concentrations of 6-oxo-PGFI,, in eight patients (24-40 years) with anticardiolipin antibodies and a history of recurrent thrombosis, and in five patients -(20-35 years) with systemic lupus erythematosus without this antibody. The anticardiolipin antibodies were measured by a modification of the original enzyme linked immunosorbent assay technique"' as described by Harris et al' and the results expressed as GPL (=IgG) or MPL (IgM) units. The results are shown in Table 1 . We previously reported that in healthy non-pregnant women plasma 6-oxo-PGF1I is less than 3 pg/ml.'7 Two of the subjects with anticardiolipin antibodies had plasma concentrations of 6-oxo-PGE1,, just above this range, i.e., 3-5 and 6-8 pg/ml. but these modest increases are consistent with venous trauma during venepuncture, which was not as easy as in healthy subjects. The remaining results were all normal. It will be of great interest to determine excretion rates of metabolites of PGI, and thromboxane in the urine of such patients as an integrated measure of the production rate throughout the body. ' use of the laboratory'. Other cultural differences emerge the commonest cause of a persistently raised uric acid level in patients receiving allopurinol is given as being due to extensive tophi. whereas compliance must be the commonest cause in the UK. Notwithstanding these quibbles. I thoroughly enjoyed the style and content of this book.
Lupus Arthritis
The major difficulty is in identifying the market for it in this country. It is too complex for undergraduates and does not contain enough detailed description of patient evaluation for MRCP candidates. Because it is not a reference book it does not replace the monoliths. It would, however, provide a sound and sensible background for any doctor embarking on a registrar or senior registrar post in rheumatology. This book is about the drugs used in the treatment of the rheumatic disorders and to some extent relates their usage to the overall management of the patient. Its stated purpose is to inform rheumatologists generally about the plethora of antirheumatic drugs on the market and to act as a means of updating previous knowledge. It should be said at the outset that it succeeds in its main aims. One of the problems with such a book, however, is the length of time between preparation and actual publication. Inevitably, therefore, some of the information is already out of date, and for instance, one of the drugs suggested as having disease modifying properties has alreadv been withdrawn. Few of the references are later than 1983. and this is an inherent difficulty in disseminating information in this way as a hard back volume. This delay becomes important when one of the stated aims is to act as an update facility.
The book is divided into three sections pharmacological
